{"id":"NCT00312195","sponsor":"Purdue Pharma LP","briefTitle":"Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain","officialTitle":"An Open-label Run-in, Followed by a Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Show the Effectiveness of Buprenorphine Transdermal System in Management of Patients With Chronic Nonmalignant Pain Syndromes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-03","primaryCompletion":"2001-07","completion":"2001-07","firstPosted":"2006-04-07","resultsPosted":"2010-10-15","lastUpdate":"2012-09-10"},"enrollment":267,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Non-malignant Pain"],"interventions":[{"type":"DRUG","name":"Buprenorphine transdermal patch","otherNames":["Butransâ„¢"]},{"type":"DRUG","name":"Placebo to match BTDS","otherNames":[]}],"arms":[{"label":"BTDS (5, 10 or 20)","type":"EXPERIMENTAL"},{"label":"Placebo to match BTDS","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10 and 20) in comparison to matching placebo transdermal system in subjects with chronic nonmalignant pain syndromes currently controlled by oral opioids. The double-blind treatment intervention duration is 2 weeks during which time supplemental analgesic medication (acetaminophen) will be provided to all subjects in addition to study drug.","primaryOutcome":{"measure":"The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase.","timeFrame":"Double-blind phase (14 days)","effectByArm":[{"arm":"Double-blind Placebo Patch","deltaMin":89,"sd":null},{"arm":"Double-blind BTDS","deltaMin":66,"sd":null},{"arm":"Total","deltaMin":155,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":".0217"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":42,"countries":["United States","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":138},"commonTop":["Nausea","Erythema at site","Pruritus at site","Dizziness","Headache"]}}